Mylan open to deals to grow OTC offering
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Mylan has expressed an interest in acquisitions to grow its burgeoning OTC portfolio, as the firm presses ahead with its goal to reach US$2.0 billion (€1.6 billion) in annual sales by 2021.
You may also be interested in...
Aspen And Mylan Strike A Deal On Australia And New Zealand Portfolio
Mylan has bolstered its presence in key Australasian markets through a portfolio distribution arrangement with Aspen Pharma, which includes an option to buy in March 2019; the South African firm, on the other hand, is continuing to manage its portfolio in the markets, “allowing enhanced operational focus and removing complexity.”
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.